RXDX-102

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameRXDX-102
Drug Alias NameTrk family tyrosine kinase receptors inhibitor (Nerviano Medical Sciences)Trk family tyrosine kinase receptors inhibitor (Ignyta)NMS-P360RXDX-102
ClassificationSmall molecules
Mechanisms of ActionNerve growth factor receptor Trk-A antagonistsNeurotrophic tyrosine kinase receptor type 3 inhibitorsNeurotrophic tyrosine kinase receptor type 2 inhibitors +[4] 
TargetsNerve growth factor receptor Trk-ANeurotrophic tyrosine kinase receptor type 2Neurotrophic tyrosine kinase receptor type 3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNerviano Medical Sciences Srl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIgnyta IncNerviano Medical Sciences Srl
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A